SCOTUS Declines to Hear Argument Over FCA “Objective Falsehood”
The U.S. Supreme Court has decline to hear argument over “objective falsehood” under the False Claims Act (FCA). This has been a hot button issue in litigation that has federal courts split and left federal contractors, and the lawyers who represent them, with no clear answers. The question posed: What evidence is required to prove […]
Purdue Pleads Guilty to Felonies, Plea Deal Receives Criticism
Purdue Pharma pleads guilty to criminal charges for illegal marketing of the its highly addictive painkiller, OxyContin. Corporations often pay penalties and fines for wrongdoing, yet criminal charges are rare. These charges include felony charges of defrauding federal health agencies and violating anti-kickback laws. The company also paid civil penalties for violating the False Claims […]
$7.3M Astellas Pharma Off-Label Marketing and FCA Settlement
Digital Journal 2014-04-16 The whistleblower attorney team of Sheller P.C. announced today that Astellas Pharma U.S., Inc. has agreed to pay $7.3 million to resolve allegations by the Sheller whistleblower client that Astellas violated the False Claims Act by submitting fraudulent claims to government healthcare programs while marketing off-label the antifungal drug Mycamine for use in children. Court […]
Sheller in Bloomberg Business on Whistleblowers and J&J $2.2B Settlement
Bloomberg Business Week 2013-12-09 Judy Doetterl was a sales representative for Johnson & Johnson (JNJ) in 2004 when federal agents placed a hidden recording device on her and sent her to tape marketing presentations at a national company sales meeting. U.S. prosecutors wanted to prove claims by Doetterl and others that J&J boosted sales by urging doctors to prescribe […]
Sheller in Philadelphia Inquirer on $2.2B Risperdal Settlement
Philadelphia Inquirer 2013-11-05 Sheller, P.C.’s representation of whistleblowers totals over $6 billion, with three of the top five pharmaceutical settlements in history: 2009: Pfizer $2.3 billion (Geodon) 2009: Eli Lilly & Co. $1.4 billion (Zyprexa) 2013: Johnson & Johnson $2.2 billion (Risperdal, Invega) and in 2010 : Astra Zeneca $520 million (Seroquel) WASHINGTON – Health-care […]
Number One in Pennsylvania for Verdicts and Settlements 2014
2014-12-19 The $2.2 Billion settlement with Johnson & Johnson Leads the Pack The Legal Intelligencer reported that the largest verdict and settlement award in Pennsylvania between August 2013 and August 2014 was handled by Sheller, P.C. with a $2.2 billion settlement over healthcare giant Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals. J&J paid the […]
